TISSUE & FFPE COHORT COLLECTIONS
Bladder cancer tissue microarrays & FFPE blocks
Compare urothelial carcinoma arrays, including primary tumors, metastatic tissue and selected treatment-follow-up collections. For FFPE blocks, share your tissue and study requirements with our team.
THE ARRAYS
Bladder cancer arrays (4)
Collection types in this TMA catalog
Explore the tissue composition and sampling groups represented in these arrays.
Bladder (UC) with IO (Pembro/Nivo) follow up data, pre treatment and post IO treatment (not donor matched)
- Approx. cores
- 20
- Approx. donors
- 20
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Available
Bladder (urothelial carcinoma) primary, matched mets & normal (non-malignant) bladder, histopath data (TA1842)
- Approx. cores
- 80
- Approx. donors
- 80
- Core diameter
- 1mm
- Clinical follow-up
- Not listed
- Molecular data
- Not listed
Bladder (urothelial carcinoma) primary & matched mets, RCC mets, histopath data (TA2764)
- Approx. cores
- 48
- Approx. donors
- 24
- Core diameter
- 1mm
- Clinical follow-up
- Not listed
- Molecular data
- Not listed
Bladder (urothelial carcinoma) with follow up data (TA2660)
- Approx. cores
- 120
- Approx. donors
- 120
- Core diameter
- 1mm
- Clinical follow-up
- Available
- Molecular data
- Not listed
No arrays match these filters
Try another search or clear the filters to see this collection.
Data labels reflect the catalog record. Review each product and datasheet for case-level coverage. Array counts do not indicate stock availability.
FFPE TISSUE BLOCKS
Bladder cancer FFPE blocks for your study
Bladder and urothelial FFPE profiles include muscle-invasive disease by cisplatin eligibility, as well as non-muscle-invasive bladder cancer.
FFPE blocks are requested by inquiry. Our team confirms tissue availability, donor matching and data coverage for your study.
Explore Bladder / urothelial cancer FFPE cohort profiles
Collection features
- Advanced disease (III/IV)
- Longitudinal data
- Primary & matched metastases
- Pre / post standard-of-care treatment
Features vary by profile and donor; confirm the required coverage for your study.
Cisplatin-eligible or cisplatin-ineligible muscle-invasive disease
Inquire about this cohortNon-muscle-invasive bladder cancer
Inquire about this cohortProfiles describe documented collections, not live inventory. Features vary by profile and donor. Pre/post treatment collections are not necessarily donor-matched; availability and required coverage are confirmed for your study.
SELECTING YOUR ARRAY
Selecting bladder cancer tissue for your study
Compare the represented tissue and the available records before choosing an array. These examples describe individual catalog entries; data coverage is specific to each array.
Bladder Cancer TMA: Immunotherapy Follow-up
This bladder urothelial carcinoma tissue microarray includes pre-treatment and post-immunotherapy samples with pembrolizumab/nivolumab follow-up data. The pre/post groups are not donor matched.
Bladder Cancer TMA: Matched & Normal Tissue
This bladder urothelial carcinoma tissue microarray includes primary tumors, matched metastases and non-malignant bladder tissue, with histopathology data. Review the array map to distinguish the tumor, metastatic and normal tissue entries.
Bladder Cancer TMA: Primary & Metastases
This tissue microarray lists primary bladder urothelial carcinoma, matched metastases and renal cell carcinoma metastases, with histopathology data. Review the array map to distinguish the listed tissue groups.


